Pfizer Keeps Teva's Generic Lipitor Out Of U.K. For Now; Wins Six Month Patent Extension
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's block against Teva's generic Lipitor in the U.K. will remain in place until a full trial later this year; pharmacies caught between the warring factions.
You may also be interested in...
Lipitor Generics Watch: FDA Has Yet To Approve ANDA For The World's #1 Drug
Mylan had pointed to June 28 as the earliest date FDA could approve atorvastatin ANDAs; the agency is continuing discussions with Ranbaxy about its exclusivity status.
Pfizer Blocks Teva's Generic Lipitor In The U.K.
Pfizer wins temporary injunction on Teva's U.K launch of generic atorvastatin; hearing scheduled for July.
Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe
Lipitor's European sales won't all disappear overnight, But the strong post-patent performance in Spain isunlikely to be replicated either.